The latest price target for Lineage Cell Therapeutics (AMEX:LCTX) was reported by HC Wainwright & Co. on February 11, 2025. The analyst firm set a price target for $9.00 expecting LCTX to fall to within 12 months (a possible NaN% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Lineage Cell Therapeutics (AMEX:LCTX) was provided by HC Wainwright & Co., and Lineage Cell Therapeutics reiterated their buy rating.

There is no last upgrade for Lineage Cell Therapeutics

There is no last downgrade for Lineage Cell Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a reiterated with a price target of $9.00 to $9.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $undefined, which is out of the analyst’s predicted range.